TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Preventive Sodium Lactate and Traumatic Brain Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* severe head trauma with a glasgow coma scale less than 9~Exclusion Criteria:~* prehospital cardiac arrest~* severe hemorrhage shock~* severe circulatory or respiratory failure~* medullar trauma~* prehospital osmotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- half sodium lactate (Type: EXPERIMENTAL): infusion of 0.5 ml/kg/day during 48 hours
- isotonic sodium chloride (Type: ACTIVE_COMPARATOR): infusion of 0.5 ml/kg during 48 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Continuous Positive Airway Pressure and Valsartan Treatments on Arterial Blood Pressure in OSAS Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* male/female over than 18 years old~* patient with an obstructive sleep apnea (apnea-hypopnea index \> or equal to 15)~* patient with weak or moderate hypertension (140 \<= SBP \< 180 mmHg and 90 \<= DBP \< 110 mmHg). Patient with antihypertensive monotherapy must stop their treatment and respect a washout period of at least 4 weeks before the screening visit. For patient treated by antialdosterone, the washout period will be of at least 8 weeks.~* negative pregnancy test~* ambulatory patient~* patient who have signed the informed consent form~* patient affiliated to social security~Exclusion Criteria:~* pregnant or nursing woman~* woman who refuses to use contraceptive method~* acute hepatic failure, biliary cirrhosis, cholestasis~* clearance of Cockcroft \< 30 ml/min/1.73m2~* kaliemia \>= 5.5 mmol/l~* acute hypertension (SBP\>= 180 mmHg and/or DBP \>= 110 mmHg)~* acute daytime sleepiness (Epworth rating scale \> 15)~* patient with a profession that is inconsistent with the continuous positive airway pressure (CPAP) treatment~* known cardiovascular pathologies~* contraindication to CPAP~* allergy to Valsartan~* patient treated with lithium~* patient treated with drug(s) acting on arterial blood pressure~* patient on tutelle or curatelle~* patient kept in detention, major protected by the law, hospitalised person~* patient currently participating in another clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 8 weeks of Valsartant treatment, 4 weeks of washout, 8 weeks of CPAP and 8 weeks of Valsartant plus CPAP treatments
- 2 (Type: EXPERIMENTAL): 8 weeks of CPAP , 4 weeks of washout, 8 weeks of Valsartant treatment and 8 weeks of Valsartant plus CPAP treatments

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Preliminary Study to Explore Clinical Endpoints in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients meeting the Rome III Diagnostic Criteria~* Loose (mushy) or watery stools within the last 3 months~Exclusion Criteria:~* Patients having hyperthyroidism or hypothyroidism

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Ramosetron group (Type: EXPERIMENTAL): oral
- Placebo group (Type: PLACEBO_COMPARATOR): oral

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Isotretinoin on The Gonads and Hirsutism

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* consisted of 40 volunteers women with PCOS (aged 18- 40 years, BMI, 18-44kg/m2) who attended our obstetrics and gynecology clinic for the treatment menstrual irregularities and hirsutism~Exclusion Criteria:~* 1)presence of any dermatologic disorder besides acne 2) presence of any systemic disease 3) exposure to any systemic treatment in the last three months that could alter ovarian reserve 4) pregnancy or lactation 5) infection diseases 6) use of antidepressants, steroidal hormone drugs, mood stabilizers, caffeine, alcohol, or tobacco 7) histories of abdominal surgery for endometriosis or ovarian surgery

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- study group (Type: ACTIVE_COMPARATOR): The study group consisted of 40 volunteers women with PCOS (aged 18- 40 years, BMI, 18-44kg/m2) who attended the obstetrics and gynecology clinic for the treatment of menstrual irregularities and hirsutism.The patients were treated with 0.6-0.8 mg/kg oral isotretinoin up to a total dose of 120-150 mg/kg. Treatment was started at 20 mg/day and gradually increased to the maximum of 40 mg/day. The patients were monitored monthly during isotretinoin treatment.
- control group (Type: NO_INTERVENTION): The control group of this study was pretreatment period of the same volunteer patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) Protocol

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Previous diagnosis of RA according to the revised 1987 criteria of the American Rheumatism Association (Arnett et al., 1988)~* patients must have a minimum of 8 tender and 4 swollen joints with disease diagnosed at least 3 months prior to screening~* patients must have been using oral or parenteral MTX for at least the previous 3 months, and at a stable dose of 7.5 to 25 mg per week for at least the previous 1 month~* women of childbearing potential must test negative for pregnancy and be using adequate birth control measures~* patients must have a documented purified protein derivative (PPD) skin test performed at prescreening.~Exclusion Criteria:~* Patients who have received any prior treatment with infliximab or with any other therapeutic agent targeted at reducing tumor necrosis factor (TNF) (e.g., etanercept, pentoxifylline or thalidomide) within the previous 3 months~* patients who are incapacitated~* history of infected joint prosthesis within the previous 5 years~* patients with a concomitant diagnosis of congestive heart failure (CHF), history of or known malignancy within the previous 5 years, cases of active or latent tuberculosis (TB), acute or chronic serious infections within the past 3 months~* known substance abuse (drug or alcohol) within the previous 3 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive Candidiasis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must be either (1) at high risk for candidiasis (1 month - \< 2 years ONLY) or (2) have a definitive diagnosis of invasive candidiasis/candidemia (ICC) (All age groups)~* Male and female patients from 1 month to less than 18 years of age.~Exclusion Criteria:~* Any patients with allergy to the drug; and any pregnant female or lactating.~* Failed previous antifungal therapy or expected to live \< 3 days.~* Patients with documented or suspected Candida meningitis.

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Anidulafungin IV (Type: EXPERIMENTAL): All subjects meeting screening criteria will receive IV anidulafungin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial Comparing Ferumoxytol With Iron Sucrose for the Treatment of Iron Deficiency Anemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria include:~1. Males and females ≥18 years of age~2. Participants with IDA defined as having:~   1. Hemoglobin \<10.0 g/deciliter (dL)~  2. Transferrin saturation (TSAT) \<20%~3. Participants who have a history of unsatisfactory oral iron therapy or in whom oral iron cannot be used~4. Female participants of childbearing potential who are sexually active must be on an effective method of birth control for at least 1 month prior to screening and agree to remain on birth control until completion of participation in the study~Key Exclusion Criteria include:~1. History of allergy to IV iron~2. Allergy to two or more classes of drugs~3. Participants on dialysis or with an estimated glomerular filtration rate \<30 mL/minute(min)/1.73 square meter (m\^2)~4. Female participants who are pregnant, intend to become pregnant, are breastfeeding, within 2 weeks postpartum, or have a positive serum/urine pregnancy test~5. Hemoglobin ≤7.0 g/dL~6. Serum ferritin \>600 nanogram/mL

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ferumoxytol (Type: EXPERIMENTAL): Participants received a total of 2 doses of IV ferumoxytol 510 milligrams (mg) (17 milliliters \[mL\]). The first IV 510 mg dose was administered on Day 1 (Baseline) and second dose 2 to 8 (5±3) days after the first dose, for a total cumulative dose of 1.02 grams (g).
- Iron Sucrose (Type: ACTIVE_COMPARATOR): Participants received an IV injection or infusion of iron sucrose 200 mg (10 mL) on Day 1 (Baseline) and on 4 other non-consecutive days over a 14-day period, for a total cumulative dose of 1.0 g. Participants receiving their first ever exposure to IV iron sucrose, received a test dose on Day 1 prior to receiving the remainder of the first dose, as prescribed in the package insert for some countries.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: DP-R213 Phase 1 Pharmacokinetics Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* IBW ±20%~* Signed the informed consent form prior to the study participation~Exclusion Criteria:~* Clinically significant disease~* Previously donate whole blood within 2 months or component blood within 1 month~* Clinically significant allergic disease~* Taken IP in other trial within 3 months~* An impossible one who participates in clinical trial by investigator's decision including laboratory test result

- Gender: MALE
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- RT group (Type: EXPERIMENTAL): combination dose of Raloxifene and Cholecaliferol and DP-R213 in order
- TR group (Type: EXPERIMENTAL): combination dose of Raloxifene and Cholecaliferol and DP-R213 in order

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Testing Glial Pathways to HAAF in Human Subjects Using Carbon 13 Magnetic Resonance Spectroscopy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male~* BMI 20.0-24.9 kg/m2~* 18-40 years old~* Willing to reside at Pennington Biomedical for 4 days~Exclusion Criteria:~* Type 1 diabetes mellitus~* Type 2 diabetes mellitus~* Fasting glucose ≥ 110 mg/dL (determined at screening visit)~* Hyperketonuria \>15 mg/dL, (determined at screening visit)~* Contraindication to MRI~* History of or current eating disorder~* History of obsessive compulsive disorder~* Current use of any medication (excluding over-the-counter pain medication)~* Contraindication to prolonged fasting~* Consume \>10 alcoholic drinks/week

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Healthy Men (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female~* Age 18-65 years~* Diagnosis of schizophrenia or schizoaffective disorder, depressed type~* Stable dose of antipsychotic for at least 4 weeks~* Able to provide informed consent~* Able to complete a cognitive battery~* Able to perform the cognitive remediation exercises~Exclusion Criteria:~* Current treatment with clozapine~* Dementia~* Seizure disorder~* Unstable medical illness~* Renal insufficiency measured as eGFR \>60mg/dL/min~* Active substance abuse: positive urine toxic screen~* Pregnancy, nursing, or unwilling to use appropriate birth control measures during participation if female and fertile.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- D-cycloserine (Type: EXPERIMENTAL): Participants will receive D-cycloserine weekly, one hour before the first cognitive remediation session of the week, for eight weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo weekly, one hour before the first cognitive remediation session of the week, for eight weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 71A/G HSD17B5 SNP and Effects of Oral Contraceptive Pill in PCOS Women

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* hirsute women with polycystic ovary syndrome~Exclusion Criteria:~* Use of any drugs known to interfere with hormone levels for at least 3 months before the study~* Women with type 2 diabetes, homa index \> 3.8, liver or renal disease or thyroid dysfunction~* Other hyperandrogenic disorders than PCOS

- Gender: FEMALE
- Minimum Age: 15 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Successful TAVR of a native aortic valve stenosis~* By iliofemoral or subclavian access~* With any approved/marketed TAVR device~* Written informed consent~Exclusion Criteria:~* Atrial fibrillation (AF), current or previous, with an ongoing indication for oral anticoagulant treatment~* Any other indication for continued treatment with any oral anticoagulant~* Known bleeding diathesis (such as but not limited to platelet count ≤ 50,000/mm3 at screening, hemoglobin level \< 8.5 g/dL or \< 5.3 mmol/l, history of intracranial hemorrhage, or subdural hematoma)~* Any indication for dual antiplatelet therapy (DAPT) for more than three months after randomization (such as coronary, carotid, or peripheral stent implantation)~* Clinically overt stroke within the last three months~* Planned coronary or vascular intervention or major surgery~* Severe renal insufficiency (eGFR \< 30 mL/min/1.73 m2) or on dialysis, or post-TAVR unresolved acute kidney injury with renal dysfunction ≥ stage 2~* Moderate and severe hepatic impairment (Child-Pugh Class B or C) or any hepatic disease associated with coagulopathy~* Iodine contrast allergy or other condition that prohibits CT imaging

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ASA + Clopidogrel (Type: ACTIVE_COMPARATOR): ASA (Acetylsalicylic acid) 75-100mg + Clopidogrel 75mg for 90 days, followed by ASA 75-100mg monotherapy
- Rivaroxaban + ASA (Type: EXPERIMENTAL): Rivaroxaban 10mg + ASA 75-100mg for 90 days, followed by rivaroxaban 10mg monotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria: - Japan: Age minimum 20 years - Subjects diagnosed with type 2 diabetes and on stable treatment in a period of 90 days prior to screening with either metformin above or equal to 1500 mg (or maximum tolerated dose), pioglitazone above or equal to 30 mg (or maximum tolerated dose), rosiglitazone above or equal to 4 mg (or maximum tolerated dose) or a combination of either metformin/pioglitazone or metformin/rosiglitazone (doses as for individual therapies). Stable is defined as unchanged medication and unchanged dose - HbA1c 7.0 - 10.5 % (53 - 91 mmol/mol) (both inclusive) Exclusion Criteria: - Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using an adequate contraceptive method throughout the trial including the 5 weeks follow-up period (adequate contraceptive measures as required by local law or practice) - Any chronic disorder or severe disease which, in the opinion of the investigator, might jeopardise subject's safety or compliance with the protocol - Treatment with glucose lowering agent(s) other than stated in the inclusion criteria in a period of 90 days before screening. An exception is short-term treatment (below or equal to 7 days in total) with insulin in connection with inter-current illness - History of chronic or idiopathic acute pancreatitis - Screening calcitonin value above or equal to 50 ng/L (pg/mL) - Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2) - Impaired renal function defined as estimated glomerular filtration rate (eGFR) below 60 ml/min/1.73 m2 per modification of diet in renal disease (MDRD) formula (4 variable version) - Acute coronary or cerebrovascular event within 90 days before randomisation - Heart failure, New York Heart Association (NYHA) class IV

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Semaglutide 0.5 mg + sitagliptin placebo (Type: EXPERIMENTAL): None
- Semaglutide 1.0 mg + sitagliptin placebo (Type: EXPERIMENTAL): None
- Sitagliptin 100 mg + semaglutide placebo 1.0 mg (Type: ACTIVE_COMPARATOR): None
- Sitagliptin 100 mg + semaglutide placebo 0.5 mg (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Computerized Tailored Intervention for Behavioral Sequelae of PTSD in Veterans

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Military Veterans, Operation Iraqi Freedom (OIF)/Operation Enduring Freedom (OEF) service preferred~* 18 years or older~* Ability to read and comprehend English~* Mild to moderate PTSD symptoms~* Cigarette smoking (preferred)~* Mild to moderate depression (preferred)~* Difficulty managing stress~* Comfortable using a computer and access to the Internet~Exclusion Criteria:~* Present with psychosis, bipolar disorder, active substance use, or cognitive impairment~* Severe depression or suicidal ideation (Patient Health Questionnaire-9)(PHQ-9 \>19)~* Severe PTSD symptoms (PTSD Symptom Checklist)(PCL-M \>73)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- All STR2IVE Participants (Type: EXPERIMENTAL): All participants who met study criteria, consented and were enrolled, were asked to complete online assessments at three timepoints(baseline, 1-month, and 3-months) and complete 2 or more behavioral programs each month. Behavioral programs and assessments were provided online via the Multibehavioral, Computerized Tailored Intervention STR2IVE.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete